The Complement Factor D pipeline drugs market research report outlays comprehensive information on the Complement Factor D targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Complement Factor D pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Complement Factor D - Drugs In Development, 2024

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers products from therapy areas such as Ophthalmology, Hematological Disorders, Genito Urinary System, and Gastrointestinal which include the indications Geographic Atrophy, Age Related Macular Degeneration, Paroxysmal Nocturnal Hemoglobinuria, Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), IgA Nephropathy (Berger’s Disease), Liver Diseases, and Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome). It also reviews key players involved in Complement Factor D targeted therapeutics development with respective active and dormant or discontinued products.

The Complement Factor D pipeline targets constitutes close to ten molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, and Preclinical stages are 2, 2, and 6 respectively.

Complement Factor D overview

Complement factor D (CFD) is a member of serine peptidases. This protease catalyzes the cleavage of factor B, the rate-limiting step of the alternative pathway of complement activation. This protein also functions as an adipokine, a cell signaling protein secreted by adipocytes. Mutations in this gene underlie complement factor D deficiency, which is associated with recurrent bacterial meningitis infections in human patients.

For a complete picture of Complement Factor D’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.